//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
New editorial Key facts about the Bundibugyo virus outbreak www.thelancet.com/journals/lan...
16d
On May 15, 2026, an outbreak of Ebola virus disease (EVD) was declared in DRC and Uganda, with WHO designating it a Public Health Emergency of International Concern on May 17. The outbreak is due to B...
www.thelancet.com
Key facts about the Bundibugyo virus outbreak
The Lancet Infectious Diseases
In this latest @escmid.bsky.social clinical guideline, a panel of 16 multidisciplinary experts provide recommendations for how to evaluate and manage patients with reported antibiotic allergies. www.clinicalmicrobiologyandinfection.org/article/S119...
13d
📣 New publication: First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib: www.clinicalmicrobiologyandinfection.org/article/S119... #hantavirus
14d
Clinical Microbiology and Infection
Clinical Microbiology and Infection
In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk
Congrats to my colleagues for this interesting analysis. Looking at patients who met DOTS criteria and receive dalbavancin in our hospital, they differ from the DOTS trial Younger, more IDU, more R-sided IE (less SSTI), and more persistent bacteremia. Yet, outcomes similar #IDSky
Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda: rapid assessment from the ESCMID Emerging Infections Subcommittee @cmijournal.bsky.social @escmid.bsky.social www.clinicalmicrobiologyandinfection.org/article/S119...
Alveolar dysregulation of host response in pneumonia and ARDS: implications for immune modulation and infection CCR Journal Watch https://criticalcarereviews.com/latest-evidence/journal-watch
9d
10d
The Emerging Infections Subcommittee just published in CMI a rapid assessment of the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda, covering the current situation and key challenges. https://ow.ly/rS5s50Z60wO
🎙️ A special bonus episode of #Communicable is coming Monday Angela Huttner & Anne-Grete Märtson talk with Daniel Bausch & Martin Grobusch on how #Bundibugyo ebolavirus differs from Zaire & what to expect in the current outbreak #IDSky #Virosky #clinmicro https://ow.ly/nm5250Z7ViE
15d
14d
13d
9d
🎙️ Just published Communicable E54: ESCMID Global Late Breakers, part 2 Hosted by our editors - Erin McCreary, PharmD, Josh Davis, Marc Bonten, Anne-Grete Märtson, Angela Huttner 🌟 Listen on #Communicable: https://share.transistor.fm/s/a8cc04bb #ESCMIDGlobal2026 #IDSky #clinmicro
The ongoing outbreak of Ebola virus disease (EVD) caused by Bundibugyo ebolavirus (BDBV) in the Democratic Republic of the Congo (DRC) and Uganda represents a major regional public health emergency wi...
www.clinicalmicrobiologyandinfection.org
Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda: rapid assessment from the ESCMID Emerging Infections Subcommittee
13d
JAMA Network Open
Jonathan Ryder, MD
In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk
Jesús Rodríguez Baño
Critical Care Reviews
10d
ESCMID
CMI Communications
CMI Communications
JAMA Network Open